Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02969798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Dec 2026 → Feb 28, 2027
See other at-risk trials from The University of Texas Health Science Center at San Antonio

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2026 to Feb 28, 2027
    • Eligibility criteria expanded, about 23 words
    • Study description expanded, about 3 words
  2. Primary completion date: Mar 2026 to Dec 2026v13
  3. Primary completion date: Dec 2024 to Mar 2026
    • Study completion date: Jul 2025 to Jul 2027
    v12
  4. Primary completion date: Jul 2023 to Dec 2024
    • Study completion date: Jul 2024 to Jul 2025
    v11
  5. Start date: Jan 2014 to Jan 1, 2014v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Primary endpoints: 15 to 3
    • Study arms: 4 to 13
    v8
  3. Primary completion date: Jul 2022 to Jul 2023
    • Study completion date: Jul 2023 to Jul 2024
    v7
  4. Primary completion date: Jul 2020 to Jul 2022
    • Study completion date: Jul 2020 to Jul 2023
    v6
  5. Collaborators: 2 to 3v5
  6. Re-verified, no change to tracked fieldsv4
  7. Primary and study completion dates: Jul 2017 to Jul 2020v3
  8. Primary and study completion dates: Jan 2017 to Jul 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
Trial Details
NCT Number NCT02969798
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Related terms Diabetes Mellitus, Type 2, Glucose Intolerance
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov